Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00069862 · ClinicalTrials.gov registry record · Phase 1
Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
A Phase 1 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00069862 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 25 participants.
The verdict
NCT00069862, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
A clinical trial designed to compare the safety and iron excretion properties of desferoxamine (DFO) and deferitrin (GT56-252), an experimental oral iron chelator.
Interventions
- DRUG Deferitrin (GT56-252)
- DRUG desferoxamine (DFO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2003-09 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00069862
The ClinicalTrials.gov registry entry for NCT00069862 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Deferitrin (GT56-252) is the first listed.
NCT00069862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00069862 about?
NCT00069862 is a clinical study titled "Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia". A clinical trial designed to compare the safety and iron excretion properties of desferoxamine (DFO) and deferitrin (GT56-252), an experimental oral iron chelator.
What is the current status of trial NCT00069862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2003-09. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00069862?
The interventions under investigation include: Deferitrin (GT56-252) (DRUG), desferoxamine (DFO) (DRUG).
Who is sponsoring clinical trial NCT00069862?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.